Zhitong Finance App News, Shiyao Group (01093.HK) announced that the Bartolizumab injection (subcutaneous injection) (product name: Enlida®) (product) authorized by the company's subsidiary, Shiyao Group Enbipu Pharmaceutical Co., Ltd., has obtained a drug registration certificate issued by the China National Drug Administration (NDRA) to treat adult systemic myasthenia gravis (GmG) patients with positive anti-acetylcholine receptor (AChR) antibodies.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.